Surgical endoscopy

Changes in weight-loss surgery use after semaglutide and tirzepatide became popular

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Recent changes in bariatric surgery utilization are not well understood.

  • Semaglutide and tirzepatide are associated with a transformation in obesity treatment.
  • The impact of these medications on bariatric surgery rates remains unclear.
  • Further investigation is needed to understand the relationship between obesity medications and surgical options.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declarations. Disclosures: Dr. Kozato, Ms. Patel, Dr. Massie, Dr. Mankowski, Dr. Ren-Fielding, and Dr. Parikh have no conflicts of interest or financial ties to disclose. Dr. Orandi has previously served on an advisory board for Boehringer Ingelheim unrelated to the submitted work. Dr. Segev has previously received payments from Sanofi, CareDx Inc, Moderna, AstraZeneca, Roche, Optum, Organ Ox, Hansa, Biosidus, and Springer unrelated to the submitted work. Dr. Chhabra has received payments from GI Windows Surgical unrelated to the submitted work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief